CITIZENS OF
SCIENCE

Regeneron encourages staff to publish their research in leading scientific journals.

The links on this page are not affiliated with Regeneron Pharmaceuticals, Inc. Links to sites outside of Regeneron are provided as a resource to the viewer. Regeneron accepts no responsibility for the content of linked sites.

FEATURED PUBLICATIONS

• INFECTIOUS DISEASES PUBLICATIONS

  • Studies in humanized mice and convalescent humans yield a SARS-CoV-2 antibody cocktail

    Science. 2020 Jun 15;eabd0827. doi: 10.1126/science.abd0827. Online ahead of print.
  • Antibody cocktail to SARS-CoV-2 spike protein prevents rapid mutational escape seen with individual antibodies

    Science. 2020 Jun 15;eabd0831. doi: 10.1126/science.abd0831. Online ahead of print.
  • A Randomized, Controlled Trial of Ebola Virus Disease Therapeutics

    N Engl J Med 2019 Dec 12;381(24):2293-2303 doi: 10 1056/NEJMoa1910993 Epub 2019 Nov 27
  • Pre- and postexposure efficacy of fully human antibodies against Spike protein in a novel humanized mouse model of MERS-CoV infection

    Proc Natl Acad Sci www.pnas.org/cgi/doi/10.1073/pnas.1510830112

• IMMUNO-ONCOLOGY PUBLICATIONS

  • A class of costimulatory CD28-bispecific antibodies that enhance the antitumor activity of CD3-bispecific antibodies

    Sci Transl Med 2020 Jan 8;12(525) pii: eaaw7888 doi: 10 1126/scitranslmed aaw7888
  • PD-1 Blockade with Cemiplimab in Advanced Cutaneous Squamous-Cell Carcinoma

    N Engl J Med. 2018 Jun 4

• IL-4/IL-13 ANTIBODY PUBLICATIONS

  • Efficacy and safety of dupilumab in patients with severe chronic rhinosinusitis with nasal polyps (LIBERTY NP SINUS-24 and LIBERTY NP SINUS-52): results from two multicentre, randomised, double-blind, placebo-controlled, parallel-group phase 3 trials

    Lancet. 2019 Sep 19. pii: S0140-6736(19)31881-1.
  • Dupilumab Efficacy and Safety in Moderate-to-Severe Uncontrolled Asthma

    N Engl J Med. 2018 Jun 28;378(26):2486-2496
  • Efficacy and Safety of Dupilumab in Glucocorticoid-Dependent Severe Asthma

    N Engl J Med. 2018 Jun 28;378(26):2475-2485
  • Two Phase 3 Trials of Dupilumab versus Placebo in Atopic Dermatitis

    N Engl J Med 2017 Mar 16;376(11):1090-1
  • Efficacy and safety of dupilumab in adults with moderate-to-severe atopic dermatitis inadequately controlled by topical treatments: a randomised, placebo-controlled, dose-ranging phase 2b trial.

    Lancet. 2016 Jan 2;387(10013):40-52
  • Dupilumab treatment in adults with moderate-to-severe atopic dermatitis

    N Engl J Med. 2014 Jul 10;371(2):130-9.
  • Dupilumab in persistent asthma with elevated eosinophil levels

    N Engl J Med. 2013 Jun 27;368(26):2455-66.

• VEGF TRAP PUBLICATIONS

  • Intravitreal aflibercept for diabetic macular edema

    Ophthalmology. 2014 Nov;121(11):2247-54.
  • The DA VINCI Study: phase 2 primary results of VEGF Trap-Eye in patients with diabetic macular edema

    Ophthalmology. 2011 Sep;118(9):1819-26.

• IL-6 ANTIBODY PUBLICATIONS

  • Efficacy and safety of sarilumab monotherapy versus adalimumab monotherapy for the treatment of patients with active rheumatoid arthritis (MONARCH): a randomised, double-blind, parallel-group phase III trial

    Ann Rheum Dis 2016 Nov 17 pii: annrheumdis-2016-210310
  • Sarilumab and Non-Biologic Disease-Modifying Antirheumatic Drugs in Patients With Active RA and Inadequate Response or Intolerance to TNF Inhibitors

    Arthritis Rheumatol 2017 69(2): 277-290

• PCSK9 ANTIBODY PUBLICATIONS

  • Alirocumab and Cardiovascular Outcomes after Acute Coronary Syndrome

    N Engl J Med. 2018 Nov 29;379(22):2097-2107
  • Efficacy and safety of the proprotein convertase subtilisin/kexin type 9 inhibitor alirocumab among high cardiovascular risk patients on maximally tolerated statin therapy: The ODYSSEY COMBO I study

    American Heart Journal (2015).
  • Characterization of Autosomal Dominant Hypercholesterolemia Caused by PCSK9 Gain of Function Mutations and its Specific Treatment with Alirocumab, a PCSK9 Monoclonal Antibody.

    Circ Cardiovasc Genet. 2015 Sep 15. pii: CIRCGENETICS.115.001129
  • Effect of alirocumab, a monoclonal proprotein convertase subtilisin/kexin 9 antibody, on lipoprotein(a) concentrations (a pooled analysis of 150 mg every two weeks dosing from phase 2 trials)

    Am J Cardiol. 2014 Sep 1;114(5):711-5.

• ADDITIONAL RESEARCH OF INTEREST

  • A Protein-Truncating HSD17B13 Variant and Protection from Chronic Liver Disease

    N Engl J Med. 2018 Mar 22;378(12):1096-1106
  • ACVR1R206H receptor mutation causes fibrodysplasia ossificans progressiva by imparting responsiveness to activin A

    Sci Transl Med 2015 7, 303ra137